MAK Capital One’s Protalix BioTherapeutics PLX Stock Holding History

MAK Capital One’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,544,139	Closed	-$7.69M	–	20
2026 Q1	$7.69M	Buy	+3,544,139	New	+$8.79M	1.13%	19

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

MAK Capital One's PLX Position: Q2 2026 in Review

MAK Capital One sold out of Protalix BioTherapeutics (PLX) in Q2 2026, closing a stake of 3,544,139 shares — an estimated $7.69M sold.

MAK Capital One first reported a position in PLX in Q1 2026 and held it in 1 quarter. The position peaked at $7.69M in Q1 2026. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

MAK Capital One reported no remaining Protalix BioTherapeutics position as of Q2 2026 after selling out during the quarter.
MAK Capital One sold 3,544,139 Protalix BioTherapeutics shares in Q2 2026, an estimated $7.69M.
MAK Capital One first reported a position in Protalix BioTherapeutics in Q1 2026 and held it in 1 quarter.
MAK Capital One's Protalix BioTherapeutics position peaked at $7.69M in Q1 2026.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on MAK Capital One's 13F filing for Q2 2026, filed 14 Aug 2026.